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In silico discovery of a FOXM1 
driven embryonal signaling 
pathway in therapy resistant 
neuroblastoma tumors
Suzanne Vanhauwaert1,2, Bieke Decaesteker  1,2, Sara De Brouwer1,2, Carina Leonelli1,2, 
Kaat Durinck1,2, Pieter Mestdagh1,2, Jo Vandesompele1,2, Karen Sermon3, Geertrui Denecker  1,2, 
Christophe Van Neste  1,2, Frank Speleman  1,2 & Katleen De Preter1,2
Chemotherapy resistance is responsible for high mortality rates in neuroblastoma. MYCN, an 
oncogenic driver in neuroblastoma, controls pluripotency genes including LIN28B. We hypothesized 
that enhanced embryonic stem cell (ESC) gene regulatory programs could mark tumors with high 
pluripotency capacity and subsequently increased risk for therapy failure. An ESC miRNA signature 
was established based on publicly available data. In addition, an ESC mRNA signature was generated 
including the 500 protein coding genes with the highest positive expression correlation with the ESC 
miRNA signature score in 200 neuroblastomas. High ESC m(i)RNA expression signature scores were 
significantly correlated with poor neuroblastoma patient outcome specifically in the subgroup of MYCN 
amplified tumors and stage 4 nonamplified tumors. Further data-mining identified FOXM1, as the major 
predicted driver of this ESC signature, controlling a large set of genes implicated in cell cycle control 
and DNA damage response. Of further interest, re-analysis of published data showed that MYCN 
transcriptionally activates FOXM1 in neuroblastoma cells. In conclusion, a novel ESC m(i)RNA signature 
stratifies neuroblastomas with poor prognosis, enabling the identification of therapy-resistant tumors. 
The finding that this signature is strongly FOXM1 driven, warrants for drug design targeted at FOXM1 
or key components controlling this pathway.
Childhood cancers have been considered as developmental disorders and differ in many aspects from adult can-
cers, including an undifferentiated cellular phenotype and a remarkable low mutational burden1. Embryonal 
tumors such as medulloblastoma, Wilms’ tumor, embryonal rhabdomyosarcoma and neuroblastoma arise due to 
disruption of normal early developmental pathways in immature progenitor cells causing differentiation arrest 
and formation of pre-malignant lesions that can subsequently develop to full blown tumors that retain distinct 
stemness characteristics1,2.
Neuroblastomas that arise mainly in very young children with a median age at diagnosis of 18 months, are 
believed to emerge from cells of the developing adreno-sympathetic nervous system1,3. In an earlier study, we 
provided support for this hypothesis through analysis of human fetal adrenal neuroblast transcriptomes which 
showed close similarity to malignant neuroblastoma gene expression profiles4. Also the few neuroblastoma driver 
genes that were identified so far, including MYCN, ALK, PHOX2B and LIN28B, are all involved in early stages 
of the sympathetic nervous system development5–7 with both LIN28B and MYCN implicated as major drivers 
of stemness8. Novel therapies targeting these neuroblastoma driver genes such as ALK inhibitors and inhibi-
tors of the BRD4-MYCN-promotor interaction are already emerging9. While these developments are promising, 
outcome of high-risk neuroblastoma patients is still disappointingly low and insights into therapy resistance 
mechanisms and new venues for targeting these resistant cells are needed. High treatment failure rates could pos-
sibly be explained by the stemness features of cancer initiating cells, including enhanced DNA repair capacity10. 
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Therefore, a more in-depth analysis of stemness features of pediatric cancers may provide new insights into ther-
apy resistance and may also offer novel targets for therapeutic intervention.
In this study, we explored the stemness features of neuroblastoma tumor cells using an in silico analysis 
starting from a normal embryonal stem cell (ESC) driven miRNA signature. This approach was based on three 
important concepts. First, several hallmark characteristics of stem cells, including the capacity to self-renewal and 
differentiation are mimicked in the highly proliferative cancer cells, suggesting that similar regulatory networks 
are active in normal stem cells and cancer stem cells11. Secondly, miRNAs are key players in the tight control of 
(stem) cell fate12. These small non-coding RNA molecules play a crucial role in stem cell pluripotency, control 
of self-renewal, lineage-specific differentiation, and cell reprogramming12. The miRNA pathway has been shown 
to be crucial in embryonic development and in embryonic stem cells, as shown by Dicer knockout analysis13. 
Specific patterns of miRNAs have been reported to be expressed only in ESCs and in early phases of embryonic 
development. Hence, regulatory networks tightly controlled by miRNAs can be assumed to play important roles 
in normal and cancer stem cell biology. Third, miRNA expression patterns can distinguish tumor types and tissue 
types better than mRNA expression patterns14. From these observations we anticipated that miRNAs could act as 
a proxy to capture stem cell features in neuroblastoma cells. Indeed, it has already been shown that miRNAs play 
important roles in neuroblastoma tumor formation and progression15,16. The let-7 cluster, previously described 
as crucial to be downregulated for maintaining pluripotency in stem cells17, is frequently lost in neuroblastoma, 
inversely associated with MYCN amplification status and independently correlated with poor prognosis18. 
Furthermore, several miRNAs have been shown to play a role in chemoresistance in neuroblastoma19.
To this end, we used a unique in silico approach to investigate the stemness characteristics in neuroblastoma 
tumor cells and obtained three important results: (1) a 60 miRNA ESC signature could discriminate patients with 
poor survival within a subset of the high-risk neuroblastoma patients; (2) biological function enrichment analysis 
on the coding genes correlated with the miRNA ESC signature score in neuroblastoma revealed increased DNA 
repair mechanisms in tumors with high stem cell capabilities driven by the FOXM1 transcription factor, which 
was further confirmed by FOXM1 knock down experiments; (3) analysis of transcriptional changes after FOXM1 
knock-down in neuroblastoma cells and re-analysis of published datasets strongly supports the contribution of 
FOXM1 to the stemness and MYCN driven tumor phenotype of neuroblastoma cells. The results of these in silico 
analyses should fuel renewed efforts for identifying novel on target compounds to block FOXM1 activation in 
high-risk neuroblastomas.
Results
Embryonic stem cell miRNA signature score analysis identifies patients with poor survival 
within a subset of high-risk neuroblastoma patients. In order to evaluate the stem cell features of 
neuroblastoma cells, we first established a robust miRNA ESC signature based on literature data. To this end, gene 
lists were retrieved from 4 published studies reporting on differential miRNA expression analysis of ESCs versus 
more differentiated cells (Supplemental Table 1)20–23. miRNA genes that were listed in at least 2 of the publications 
were included in the ESC signature (Table 1). A gene cluster with a well-known role in ESCs is the miR-302/367 
cluster, of which all components are present in the signature. Using signature score analysis (see material and 
methods), we could validate the signature in an independent dataset of ESCs with high miRNA signature scores 
for the ESC samples compared to differentiated somatic tissue (Supplemental Fig. 1)24.
Next, we generated miRNA expression data of ESCs25, normal neuroblasts and neuroblastoma tumor sam-
ples4,26. We confirmed high scores for the ESCs compared to those of neuroblastoma tumor samples (Fig. 1A). The 
normal counterpart cells, i.e. the normal neuroblasts isolated from fetal adrenal glands, have ESC miRNA signa-
ture scores in the higher range of the scores identified in neuroblastoma tumors samples. The large dynamic range 
of scores in neuroblastoma tumors warranted us to evaluate whether this heterogeneous expression pattern could 
reflect tumor characteristics including MYCN status and patient survival. Indeed, tumors presenting with MYCN 
amplification have significantly higher signature scores than MYCN single copy tumors (t-test, p-value = 4.282e-
05) (Fig. 1B). In addition, Kaplan-Meier and log-rank analysis pointed at a significant correlation with survival, 
i.e. patients with higher scores have lower survival chances (Fig. 1C,D). According to multivariate logistic regres-
sion analysis, this significant correlation is independent of the currently used risk markers, i.e. MYCN status, stage 
(stage 4 versus other stage) and age at diagnosis (below or above 1 year) (Odds’ ratio 3.08, p = 2.16E-2 for the 
signature score using median cut-off). More specifically, MYCN single copy stage 4 tumors with high ESC miRNA 
signature scores (above the median score) have extremely low survival probability, i.e. 19.6% overall survival at 5 
years after diagnosis (95% confidence interval: 7.52–51.1%) versus 69.5% (52.6–91.9%) in tumors with low ESC 
miRNA signature scores (Fig. 1E,F).
Taken together, these data indicate that highly aggressive neuroblastoma cells in patients with ultra-high risk 
and very poor survival are enriched for a stemness ESC derived gene signature and that application of this signa-
ture could be helpful for early detection of patients for novel treatment strategies.
The ESC miRNA signature score is dynamically upregulated during MYCN driven tumor for-
mation and is highest in the ALKF1174L/MYCN double transgenic mice. In the tyrosine hydroxylase 
(Th)-MYCN neuroblastoma mouse model, a clear increase in the ESC miRNA signature score during tumor 
development from pre-neoplastic lesions in the ganglia at week 1 and 2 to full-blown tumors at week 6 after 
birth is observed (Fig. 1G)27. Furthermore, Th-MYCN- and also dopamine beta hydroxylase (dβh)-iCre; LSL- 
ALKF1174L-, and dβh-iCre; LSL-LIN28B-driven mice tumors are characterized by higher ESC miRNA signature 
scores compared to normal adrenal gland (Fig. 1H)7,28. Interestingly, the ESC miRNA signature score in dou-
ble transgenic mice tumors (MYCN/ALKF1174L) is significantly higher than in ALKF1174L-driven tumors (signifi-
cant difference with p = 1.905E-2), in concordance with shorter time to tumor appearance and thus more tumor 
aggressiveness in double transgenic mice compared to ALKF1174L-transgenic mice (Fig. 1H).
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Overall, these results generated in human and mice tumors show that a high ESC signature score is linked 
to higher tumor aggressiveness, in keeping with the observed poor survival in patients with tumors with high 
miRNA ESC score.
The ESC mRNA gene signature in neuroblastoma is highly enriched for FOXM1 driven cell cycle 
and DNA repair genes. In order to understand the underlying biological functions of high miRNA ESC 
signature scores in aggressive neuroblastoma, Gene Set Enrichment Analysis (GSEA) analysis was performed on 
the list of coding genes ranked according to degree of expression correlation with the ESC miRNA signature score 
in 200 NB tumor samples (Supplemental Table 2). Gene sets enriched among the positively correlated genes are 
involved in chromatin remodeling, response to DNA damage (double strand DNA breaks) and cell cycle (MSigDB 
c5-gobp) as well as embryonic stem cells (MSigDB c2-cgp) and MYC and E2F targeting (MSigDB Hallmark gen-
esets) (adjusted p-values < 0.001) (Fig. 2A–F). These findings were confirmed by DAVID-gene ontology analysis 
on the top 500 correlated genes showing enrichment for cell cycle and DNA damage/repair genes (functional 
annotation clustering: first cluster with cell cycle gene sets has enrichment score of 41.93, second cluster with 
DNA damage/repair functional classes has enrichment score of 29.52, cut-off for significance is 1.3).
We also performed motif enrichment analysis using iRegulon29 to identify transcription factors that drive 
the expression of the top 500 correlated genes, further referred to as the ESC mRNA signature (Supplemental 
Table 3)29. Within the top 10 most significantly enriched transcription factors, several members of the DREAM 
complex, which has an important role in transcriptional repression of cell cycle genes and maintaining quiescence, 
are present including E2F, MYBL2 and FOXM130. Dream-complex members FOXM1, MYBL2, E2F1/2/3/7/8 and 
LIN9 are all part of the top 500 correlated gene list. Furthermore, FOXM1 is a transcription factor known to target 
several genes involved in the enriched DNA repair pathway, including EXO1, BRIP1, BRCA1, BRCA2, CHEK1, 
BUB1B, XRCC2 and RAD51AP1k, all of which are in the top 50 of the ESC mRNA signature31. Also part of the 
gene list is CENPF which is a known FOXM1 target that cooperates with FOXM1 as recently shown for prostate 
cancer32, as well as MELK, CDK6, PLK1 which are all described as regulators of FOXM1 phosphorylation33. 


































Table 1. ESC miRNA signature.
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Interestingly, the expression of 3 of these genes i.e. MELK, MYBL2 and PLK1 is remarkably highly correlated with 
FOXM1 expression levels in 200 neuroblastoma tumors (correlation coefficients >0.9) suggesting a very tight 
co-regulated transcriptional control.
Furthermore, similar as to the ESC miRNA signature, ESC mRNA signature scores are related to survival in 
a global cohort of neuroblastoma tumors, but also in a subgroup of stage 4 tumors without MYCN amplification 
(Supplemental Fig. 2A–D). This observation is confirmed in an independent dataset of 498 neuroblastoma tum-
ors (Supplemental Fig. 2E–H)34.
Collectively, our findings support that the ESC mRNA gene signature in neuroblastoma is also related to patient 
survival and most interestingly is highly enriched by components of a FOXM1 controlled regulatory network.
Differentially expressed genes after FOXM1 knock-down in neuroblastoma cells are enriched 
for mRNA ESC signature genes. To investigate the effect of FOXM1 knock-down on the transcrip-
tional profile and more particularly the ESC mRNA gene signature, we performed FOXM1 knock down and 
gene expression profiling in the neuroblastoma cell line IMR-32 with high ESC mRNA signature score and 
high FOXM1 expression levels (4 biological replicates) (Supplemental Fig. 3A). Upon lentiviral transduction of 
shFOXM1 in IMR-32, we observed strong knockdown of FOXM1 expression levels (Supplemental Fig. 3B,C). In 
addition, genes downregulated upon shFOXM1 were significantly enriched for described FOXM1 direct target 
genes identified using ChIP-sequencing (Fisher’s Exact test p = 7.564e-15 and p = 2.758e-10)35,36. Subsequent 
GSEA of down regulated genes after FOXM1 knock-down revealed enrichment for gene sets related to DNA 
repair, E2F and MYC targeting (MSigDB Hallmark genesets) (Fig. 3A–C). Of further note, the 500 ESC gene 
set is also significantly enriched in the IMR-32 FOXM1 knock-down data (Fig. 3D) (GSEA-analysis, adjusted 
p-values < 0.001). This is also confirmed in other cancer types where the ESC mRNA signature goes down upon 
chemical and pharmacological FOXM1 knock-down (Supplemental Fig. 4)37–39.
Taken together, this experimental analysis further supports the data-mining driven observation that the ESC 
mRNA gene signature in neuroblastoma cells is enriched for genes that are transcriptionally regulated by FOXM1.
In silico evidence for an activating role of MYCN on ESC genes in keeping with direct binding of 
MYCN to the FOXM1 promotor. Previous work has provided evidence for a coordinated role of MYC and 
FOXM1 in controlling normal S-phase progression in mouse embryonic stem cells40. Furthermore, as indicated 
Figure 1. Identification of an ESC miRNA signature score that stratifies neuroblastoma patients within 
a subset of high-stage neuroblastoma. (A) ESC miRNA signature scores in embryonic stem cells (ESC 
line)25, neuroblastoma tumors (NB tumors)26 and normal neuroblasts4 (the error bars represent standard 
deviations, p-values from Mann-Whitney tests). (B) ESC miRNA signature scores in MYCN non amplified 
neuroblastoma tumors (MNA) compared to MYCN amplified neuroblastoma tumors (MA) (p-value from 
t-test). (C,D) Kaplan-Meier and log rank analysis of 200 neuroblastoma patients with a high or low ESC miRNA 
signature score (using median as cut-off). DOD, dead of disease. (E,F) Kaplan-Meier and log rank analysis 
within the subset of stage 4 MYCN non amplified patients. (G) ESC miRNA A signature score during tumor 
development in Th-MYCN transgenic mice. (H) ESC miRNA signature scores for MYCN, ALKF1174L and Lin28b 
neuroblastoma mice tumors and their normal counterparts (adrenal gland and brain tissue) (p-value from 
Mann-Whitney test).
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above, we observed MYC target gene enrichment in the genes downregulated upon FOXM1 knock-down. Therefore, 
we further investigated MYCN controlled regulation of the FOXM1 gene signature in neuroblastoma context. To 
this end, we reanalyzed data of several in vitro MYCN neuroblastoma model systems. In these datasets, we observed 
decreased ESC mRNA signature scores and FOXM1 expression levels upon MYCN knock-down and pharmaco-
logical MYCN activity inhibition using JQ1 and OTX015 (Fig. 4A–C)41–43. Also in the Th-MYCN mouse model an 
increase in ESC mRNA signature score and FOXM1 expression is observed upon MYCN driven development from 
hyperplastic ganglia towards full-blown neuroblastoma tumors (Fig. 4D)27. Remarkably, the expression of all top 
50 correlated genes from the ESC mRNA signature, including FOXM1, increases upon Th-MYCN driven neuro-
blastoma development (Fig. 4E). In neuroblastoma tumors, the ESC mRNA signature score is significantly higher 
in tumors with versus without MYCN amplification (both in the global cohort and the subset of stage 4 tumors) 
(Fig. 4F,G Supplemental Fig. 2I,J). Interestingly, higher ESC mRNA signature scores were also observed in other 
tumor(cell line)s with MYCN amplification (Supplemental Fig. 5)44,45. Altogether, these data point to an important 
role of MYCN in the regulation of the ESC signature genes. Therefore, we further investigated the possible binding of 
MYCN to the FOXM1 promotor region using published ChIP sequencing data for MYCN46 and subsequent analysis 
of binding sites at or near the FOXM1 promotor. In these data, direct binding of MYCN on the FOXM1 promotor 
is clearly observed in both MYCN amplified and non-amplified high MYCN expressing cell lines (Fig. 4H). Strong 
MYCN binding promotors are highly enriched for the canonical E-box (CACGTG), and a canonical E-box motif is 
found at the transcription start site of FOXM1, indicative for a strong interaction between MYCN and the FOXM1 
promotor. Also, MYCN binding to the strong promotor associated site of FOXM1 is only decreased 24 hours after 
MYCN shutdown while at other loci with weaker binding sites MYCN binding is lost already 2 hours after MYCN 
downregulation in SHEP-21N cells. This further shows that reduced binding of MYCN at the FOXM1 promotor 
only occurs when MYCN is already depleted from weaker MYCN binding sites. Altogether, these data suggest that 
MYCN acts a driver (or co-driver) of the FOXM1 controlled ESC signature.
Discussion
Stem cell like (stemness) gene signatures have been shown to hold prognostic power in several cancer types11. 
Given that (1) neuroblastoma is an embryonal neural crest derived tumor, (2) MYCN is critical for the mainte-
nance of embryonic stem cell-derived neural crest stem cells8 and (3) LIN28B, a known stem cell marker, acts as 
oncogene in neuroblastoma7, we decided to explore whether an ESC derived miRNA signature could capture a 
Figure 2. Important genesets found to be enriched using GSEA on the list of coding genes ranked according 
to the degree of correlation with the ESC miRNA signature score in 200 neuroblastoma patient samples. 
NES = nominal enrichment score; FDR = false discovery rate.
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stemness phenotype in neuroblastoma cells and be applied as tool to select neuroblastoma patients with therapy 
resistant tumors. Having established an ESC derived miRNA prognostic classifier, we could indeed show that 
within the subgroup of high-risk patients we were able to predict with high confidence patients that would not 
benefit from current treatment regimes. Indeed, neuroblastoma patients with a high ESC miRNA signature score 
have more chance to die of disease or relapse as illustrated in Kaplan-Meier analyses. The survival difference for 
tumors with different scores is most striking for high-stage neuroblastoma tumors without MYCN amplification, 
while all tumors with MYCN amplification have higher ESC miRNA signature scores compared to non-amplified 
tumors. This prognostic classifier could thus be helpful to identify patients in a subset of high-stage cases that 
would be eligible for phase I trials for novel compounds in so-called basket trials47.
To understand the key drivers of the high ESC signature scores and possible cause of therapy resistance mech-
anisms in ultra-high risk neuroblastomas and as a prelude to drugging the stemness phenotype in neuroblastoma, 
we applied a unique data mining approach. We established mRNA signature derived from correlation analysis 
of the initial ESC miRNA signature score with gene expression profiling data in a large set of primary human 
neuroblastomas. Functional and motif enrichment analysis on the top 500 correlated genes, further referred to 
as the ESC mRNA signature, pointed at a central role of transcription factor FOXM1 and several other members 
of the DREAM complex, including MYBL2, E2F and LIN9 in controlling the stem cell characteristics of aggres-
sive neuroblastoma cells, by keeping cell cycle and DNA repair mechanisms in check. The DREAM complex has 
an important role in cell cycle by coordinating the shift from quiescence to proliferation30. When cells exit the 
G0 phase, FOXM1 and MYBL2 are recruited to promote mitotic gene expression30 thereby controlling proper 
DNA replication and avoiding excessive genomic damage30. Binding of FOXM1 to G2/M promotors is dependent 
upon MYBL2, further revealing a tight interaction between both proteins48. MYBL2 has also been shown to be 
Figure 3. Important genesets found to be enriched using GSEA upon knock down of FOXM1 in IMR32. 
NES = nominal enrichment score; FDR = false discovery rate.
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a downstream target of MYCN in neuroblastoma and the cells are addicted to MYBL2 in a MYCN dependent 
manner49. Both genes have been described to have a role in sustaining the self-renewal capacity of pluripotent 
stem cells40, and renewal of neural progenitor cells and survival of neuroblastoma cells50. In further support of 
a role for FOXM1 in neuroblastoma, Zha et al. reported high MEIS2 levels which is a transcription activator of 
the MuvB-BMYB-FOXM1 complex with FOXM1 being a direct target gene of MEIS2 and required for MEIS2 to 
upregulate mitotic genes51.
Given our findings and these data from the literature, we propose this regulatory axis as an important novel 
therapeutic vulnerability for neuroblastoma.
Next, we further explored the link between MYCN and stemness8 through further analysis of several MYCN 
model systems, i.e. the dynamic regulated transcriptome of Th-MYCN driven mouse neuroblastomas27, neuro-
blastoma cell lines upon knock-down of MYCN expression41 and upon pharmacological inhibition of MYCN 
activity42,43. Collectively, these data demonstrate correlation of high ESC mRNA signature scores with high 
MYCN activity, further confirmed by high ESC mRNA signature scores in MYCN amplified human tumors com-
pared to non-MYCN amplified cases. Not unexpectedly, a subset of high-stage neuroblastoma tumors without 
MYCN amplification also have elevated ESC signature scores, in keeping with high MYC activity in these cells. 
Similar as with the miRNA ESC signature, this subgroup of neuroblastoma patients is marked by very poor sur-
vival outcome.
Interestingly, our ESC mRNA gene set shows a very strong overlap with a gene set recently derived by Olsen 
et al.52 in a novel mouse neural crest derived neuroblastoma model. In brief, this study describes how mouse 
neural crest cells are grown and differentiated in vitro to generate sympathetic progenitor cells. Subsequently, 
these cells were transduced with MYCN and injected into mice to generate neuroblastomas. Analysis of the 
MYCN upregulated genes in the resulting mouse tumors also showed a strong enrichment of FOXM1 controlled 
genes involved in cell cycle and DNA damage control corroborating our data in human primary tumors and the 
Th-MYCN mouse model.
In a huge pan-cancer dataset including ~18.000 tumors, a FOXM1 regulatory network was identified as a 
major predictor of adverse outcome across different tumor entities53, matching with the described link of FOXM1 
with cancer therapy resistance54 and its role in DNA damage control31 as observed in stem cells and tumors like 
neuroblastoma. In the light of the studies that pinpoint FOXM1 as an important pan-cancer gene, several labs are 
undertaken efforts to identify drugs that target FOXM1. The past years, several drugs presumed to target FOXM1 
Figure 4. Association between MYCN and FOXM1 in the ESC mRNA signature score. (A) ESC 
mRNA signature score upon lentiviral knock-down of MYCN in IMR-32 neuroblastoma cells, (B) upon 
pharmacological inhibition of MYCN with JQ1 in SKNBE(2)-C and Kelly neuroblastoma cells, (C) after 
inhibition of MYCN with JQ1 and OTX015 in IMR-5 neuroblastoma cells (p-values from Mann-Whitney 
tests), and (D) during tumor development in Th-MYCN mouse model. (E) Heatmap of expression of the top 50 
correlated genes of the ESC mRNA signature in the Th-MYCN mouse model. (F,G) ESC mRNA signature score 
in neuroblastoma patient samples with and without MYCN amplification in a global cohort (F) and in stage 4 
neuroblastoma patient samples (G). (H) ChIP-seq profiles of H3K27 and MYCN transcription factor binding 
at the FOXM1 promotor in both MYCN amplified (NGP, BE2C, KELLY) and MYCN non amplified (CLB-GA, 
qval = 6.3 × 10−5) cell lines as well as the SHEP21N cell line with induced MYCN expression.
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activity have been reported but so far none of these drugs has been successfully applied in the clinic, possibly due 
to off target and or insufficient on target effects of these drugs. While our study warrants further drug screening 
for more potent and specific FOXM1 inhibitors39, it is also of great interest that the FOXM1 upstream regulatory 
kinase MELK is also highly expressed, suggesting that this could act as a good candidate drug target for ultra-high 
risk neuroblastoma patients. More recently, a specific MELK inhibitor, MELK-T1 was tested, and could represent 
a useful novel drug for improving survival rates for children with neuroblastoma55.
Similar as our ESC miRNA signature, Ittai Ben-Porath et al.11 has built an ESC mRNA signature consisting of 
380 genes overexpressed in ESC according to 5 or more out of 20 profiling studies and could show an association 
to prognosis in breast cancer. We tested this mRNA signature in expression data of 200 neuroblastoma tumors 
and could show correlation of high signature score with worse outcome in the global patient cohort, but not in 
the subset of high-stage tumors without MYCN amplification (data not shown). Moreover, the signature did not 
contain the DREAM complex genes, FOXM1, MYBL2, LIN9 and E2F. Thus, our unique approach did not only 
lead to more strong and robust prognostic signatures, but also revealed some putative mechanism of therapy 
resistance in neuroblastoma.
In conclusion, by (re)analysis of published and unpublished expression profiling data, we could unravel a 
MYC(N)-FOXM1-ESC signaling axis that is active in therapy resistant neuroblastoma tumors and that unveils 
new vulnerable nodes for targeted therapy of tumors where current treatment regimens fail.
Materials and Methods
Re-analysis of publicly available datasets. In this study, we reanalyzed several published expression 
datasets: miRNA expression data of different embryonal stem cell lines and differentiated tissue (GSE34199)20–24, 2) 
miRNA expression data of 200 neuroblastoma tumor samples26, 3) matching mRNA expression profiling data 
of the same 200 samples (GEO85047), 4) RNA sequencing data of 498 neuroblastoma tumors (GSE62564, 
GSE49711)34, 5) miRNA and mRNA expression data of the Th-MYCN neuroblastoma progression model 
(E-MTAB-2618)27, 6) miRNA expression data of the different neuroblastoma mouse models7,27, 7) mRNA expres-
sion data of the shMYCN knock-down system (GSE39218)41, 8) mRNA expression data of JQ1 and OTX015 
treated neuroblastoma cell lines (GSE43392, E-MTAB-3672)42,43, 9) mRNA expression profiling data of siFOXM1 
treated breast cancer cells (GSE55204, GSE25741)56,57 and shFOXM1 treated glioma cells (GSE63963)58, 10) 
mRNA expression profiling data of glioma, prostate, and breast cancer cell lines after pharmacological inhibition 
of FOXM1 with siomycinA and FDI-6 (GSE50227, GSE36531, GSE58626)37–39, 11) data of the cancer cell line 
encyclopedia59 and 12) medulloblastoma mRNA expression data (GSE30530)45. The R-package GEOquery and 
ArrayExpress were used to download the publicly available (normalized) data directly into the R-environment. 
ChIP-seq data of MYCN and H3K27ac in BE2C, Kelly, NGP and SHEP21N were downloaded from ArrayExpress 
(E-GEOD-80154) and converted to bigwig files to visualize the ChIP tracks in IGV.
miRNA profiling of normal neuroblasts and human embryonic stem cell lines. MiRNA expres-
sion of 8 embryonal stem cell lines25 and 7 normal neuroblast samples4 was profiled and normalized as previously 
described60 (data submitted to a data repository (accession number GSE121513).
Data-mining and statistical analysis. We performed signature score analysis on both mRNA and 
miRNA expression data using a rank-scoring algorithm as described in61. In brief, for each tumor sample (mRNA 
or miRNA) expression values were transformed to ranks (a rank of 1 matching with the lowest expressing gene). 
Next, rank scores for the signature genes were summed for each sample generating a signature score.
Correlation of the score with survival was tested using Kaplan-Meier plots and log-rank analysis by grouping 
the samples in 2 equal groups (score above or below the median value) (R-survival package). Comparison of sig-
nature scores or expression between groups of samples was done using the parametric t-test or non-parametric 
Mann-Whitney test (R-base package). Signature score and gene expression correlation analysis was performed 
using Pearson correlation analysis (R-base package). GSEA62 was performed using the version 5.2 geneset cata-
logue. Multivariate logistic regression analysis was performed on a subset of samples including only the patients 
that died of disease or survived for at least 3 years after diagnosis.
FOXM1 gene silencing through shRNA knock-down and verification of knock down by RT-qPCR 
and Western Blot analysis. ShRNA knock down for FOXM1 was achieved using MISSION shRNA (Sigma) 
TRCN0000015544. Viral production was performed as instructed by the manufacturer (Lifetechnologies) and the 
obtained virus was afterwards transduced in the neuroblastoma cell line IMR-32.
24 h after transduction the medium was refreshed and cells were selected with puromycin (0.5 µg/ml). 
Cells were harvested for RNA 96 h after transduction and RNA isolation was performed using the miRNeasy 
micro kit (Qiagen, catalogue number 217084), including DNAse treatment on column (RNAse-free DNAse set, 
Qiagen, catalogue number 79254). cDNA synthesis was carried out using 500 ng of RNA with the iScript 
cDNA synthesis kit (Bio-Rad, catalogue number 170–8891). RT-qPCR primers for FOXM1 (AGACACCCA 
TTAAGGAAACG,TTTGTACTGGGCTGAAATCC) and reference genes HPRT1(TGACACTGG 
CAAAACAATGCA,GGTCCTTTTCACCAGCAAGCT), YWHAZ(ACTTTTGGTACATTGTGGCTTCAA, 
CCGCCAGGACAAACCAGTAT), SDHA (TGGGAACAAGAGGGCATCTG, CCACCACTGCATCAAAT 
TCATG) were designed using primerXL (www.primerXL.org). RT-qPCR reactions were performed in duplicate 
in a total volume of 5 µl, including 2 µl of cDNA and 3 µl of ssAdvanced SYBR Green qPCR mastermix (Bio-Rad). 
Cycling conditions were 95 °C (15 s) – 60 °C (15 s) – 72 °C (60 s) and 44 cycles. Data analysis was performed using 
the qBasePlus software (Biogazelle). Protein extraction was done via RIPA buffer and protein concentration was 
measured using the Lowry protein assay. Protein extracts were separated with SDS-PAGE, blotted on a nitrocellu-
lose membrane and probed with antibodies against FOXM1 (1/1000; 5436 S cell signaling), and β-actin (1/10000, 
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A2228, Sigma-Aldrich). Proteins were detected with HRP-conjugated goat anti rabbit IgG antibody (1/15000, 
A27036, thermos fisher scientific) and developed with ChemiDoc-it imaging system (UVP).
Differential gene expression analysis by RNA sequencing of FOXM1 knock-down in neuroblas-
toma cells. Poly-A captured RNA library preparation was done on biological quadruplicates of FOXM1 
knock-down and control samples, using the TruSeq stranded mRNA kit LT. Concentration was measured via 
qPCR using the Kapa Library Quantification Kit (Illumina) and 1.4pM was loaded on a NextSeq. 500. NextSeq. 
500 High Output V2 75 cycles kit was used for single end sequencing to obtain approximately 20 million reads 
for every sample.
Sample and read quality was checked with FastQC (v0.11.3). Reads were subsequently aligned to the human 
genome GRCh38 with STAR aligner (v2.5.2b). Final gene count values were obtained with RSEM (v1.2.31), which 
takes read mapping uncertainty into account.
Counts were normalized with the TMM method (R-edgeR package), followed by voom transformation 
and differential expression analysis with limma (R-limma package). GSEA62 was performed on the list ordered 
according to differential expression statistic value (t).
ChIP-sequencing of MYCN and H3K27ac in neuroblastoma cell line CLB-GA. In addition to pub-
lished ChIP-seq data, we also performed ChIP-seq in the non-MYCN amplified CLB-GA cell line. Chromatin 
immunoprecipitation for MYCN and H3K27ac was done in fifty million CLB-GA cells using 12.5 µg of 
MYCN-specific (Santa-Cruz, B8.4.B, sc-53993) and H3K27ac-specific (Abcam, ab4729) antibody according the 
ChIP-protocol described in63. DNA was subsequently adaptor ligated and amplified using the NebNext Ultra 
DNA Library Prep Kit (E7370S) and sequenced on the NextSeq. 500 using the NextSeq. 500 High Output Kit V2, 
75 cycles kit (Illumina). Raw reads were mapped to hg19 reference genome using Bowtie2 and peakcalling was 
performed using MACS2. Bigwig files were generated to visualize the ChIP-seq tracks in IGV.
Neuroblastoma cell lines. The CLB-GA cell line was obtained from the lab of Valerie Combaret (Lyon, 
France).
The IMR-32 cell line was obtained from the lab of Rogier Versteeg (Amsterdam, The Netherlands).
All cell lines were screened upon initiation in the lab with the MycoAlert Detection Assay (cat nr. LT07–318, 
Lonza) and immediately expanded for freezing in order to assure Mycoplasma free cells as a stock. Routinely 
monthly random screenings are done, which are each time completely negative. CLB-GA and IMR32 were pas-
saged two times prior to the experiments. All cell lines were routinely STR genotyped, to ensure the authenticity 
of the cell lines.
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